Abstract
The aim of our study was to analyze the distribution of HLA-DQB1 in Czech patients with central hypersomnias and differences between diagnostic groups of narcolepsy type 1 (NT1), type 2 (NT2), idiopathic hypersomnia (IH) and no central hypersomnia subjects (no-CH). Statistical analysis of DQB1 genotyping was performed on the cohort of 716 patients (375 men, 341 women) with reported excessive daytime sleepiness. DQB1*06:02 allele was present in 94% of the NT1 patients. The decrease of DQB1*06:03 allele was also confirmed. No other DQB1*06 allele nor any other DQB1 allele group was differently distributed in the NT1. In the cohort of NT2 patients DQB1*06:02 allele was present in 43%. Allele group DQB*05 was detected with a significantly higher frequency in this diagnostic unit. Any differences in presence of DQB1*05 alleles in NT2 patients were not reported so far. The cohort of patients with IH did not show any difference in allele distribution of DQB1 alleles/allele groups comparing to healthy controls. DQB1*06:02 allele was significantly increased in the no hypersomnia group. No other DQB1 allele/allele group had any difference in distribution in patients comparing to healthy controls. The different distribution of DQB1*06:02 and other DQB1 alleles/allele groups was detected in analyzed diagnostic groups. These results indicate that DQB1 contributes to the genetic predisposition to NT1, NT2, IH and no-CH in different manners.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Academy of Sleep Medicine (2014) The international classification of sleep disorders, 3rd edn (ICSD-3). ISBN 978-0991543410. http://www.esst.org/adds/ICSD.pdf. Accessed 29 Aug 2014
Anderson KN, Pilsworth S, Sharples LD et al (2007) Idiopathic hypersomnia: a study of 77 cases. Sleep 30:1274–1281
Andlauer O, Moore H 4th, Hong SC et al (2012) Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep 35:1247–1255
Aran A, Lin L, Nevsimalova S et al (2009) Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32:979–983
Berkowski JA, Shelgikar AV (2016) Disorders of excessive daytime sleepiness including narcolepsy and idiopathic hypersomnia. Sleep Med Clin 11:365–378
Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58:882–893
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
Dobrovolna M, Jiraskova K, Sonka K et al (2007) HLA association with narcolepsy in Czech patients. Abstracts for the 21st European Immunogenetics and Histocompatibility Conference, Barcelona, Spain, May 5–8, 2007. Tissue Antigens 69:373–532
Fleiss JL (1981) Statistical methods for rates and proportions, 2nd edn. Wiley, New York
Goel N, Banks S, Mignot E et al (2010) DQB1*0602 predicts interindividual differences in physiologic sleep, sleepiness and fatigue. Neurology 75:1509–1519
Gonzalez-Galarza FF, Takeshita LY et al (2015) Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acid Res 43:D784–D788
Han F, Lin L, Li J et al (2012) HLA-DQ association and allele competition in Chinese narcolepsy. Tissue Antigens 80:328–335
Heidbreder A, Frauscher B et al (2016) Not only sleepwalking but NREM parasomnia irrespective of the type is associated with HLA DQB1*05:01. J Clin Sleep Med 12:565–570
Hohjoh H, Terada N, Honda Y et al (2001) Negative association of the HLA-DRB1*1502-DQB1*0601 haplotype with human narcolepsy. Immunogenetics 52:299–301
Hong SC, Lin L et al (2007) DQB1*0301 and DQB1*0601 modulate narcolepsy susceptibility in Koreans. Hum Immunol 68:59–68
Hor H, Kutalik Z et al (2010) Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet 42:786–789
Lecendreux M, Bassetti C et al (2003) HLA and genetic susceptibility to sleepwalking. Mol Psychiatry 8:114–117
Liblau RS, Vassalli A, Seifinejad A et al (2015) Hypocretin (orexin) biology and the pathology of narcolepsy with cataplexy. Lancet Neurol 14:318–328
Lin L, Hungs M, Mignot E (2001) Narcolepsy and the HLA region. J Neuroimmunol 117:9–20
Littner MR, Kushida C et al (2005) Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 28:113–121
Martins-da-Silva A, Lopes J et al (2014) Usefulness of genetic characterization of narcolepsy and hypersomnia on phenotype definition: a study in Portuguese patients. Rev Neurol 58:49–54
Maski K, Owens JA (2016) Insomnia, parasomnias, and narcolepsy in children: clinical features, diagnosis, and management. Lancet Neurol 15:1170–1181
Mignot E, Lin X, Arrigoni J et al (1994) DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 17:60–67
Mignot E, Hayduk R, Grumet FC et al (1997) HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 20:1012–1020
Mignot E, Young T, Lin L et al (1998) Reduction of REM sleep latency associated with HLA-DQB1*0602 in normal adults. Lancet 351:727
Mignot E, Young T et al (1999) Nocturnal sleep and daytime sleepiness in normal subjects with HLA-DQB1*0602. Sleep 22:347–352
Mignot E, Lin L et al (2001) Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 68:686–699
Mignot E, Lammers GJ et al (2002) The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59:1553–1562
Miyagawa T, Toyoda H et al (2015) An association analysis of HLA-DQB1 with narcolepsy without cataplexy and idiopathic hypersomnia with/without long sleep time in a Japanese population. Hum Genome Var 2:15031
Nishino S, Okura M, Mignot E (2000) Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Review article. Sleep Med Rev 4:57–99
Noble WS (2009) How does multiple testing correction work? Nat Biotechnol 27:1135–1137
Partinen M, Kornum BR et al (2014) Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol 13:600–613
Pelin Z, Guilleminault C, Risch N et al (1998) HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups: US Modafinil in Narcolepsy Multicenter Study Group. Tissue Antigens 51:96–100
Peyron C, Faraco J et al (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991–997
Robinson J, Halliwell JA et al (2015) The IPD and IPD-IMGT/HLA Database: allele variant databases. Nucleic Acids Res 43:D423–D431
Roth B, Nevsimalova S et al (1985) A study of the occurrence of HLA DR2 in 124 narcoleptics: clinical aspects. Schweizer Arch Neurol Psychiatr 139:41–51
Sonka K, Pazderova L et al (2014) The value of repeated non-confirmatory multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Cesk Slov Neurol 77(110):444–448
Tafti M, Hor H et al (2014) DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep 37:19–25
Tate MW, Brown SM (1970) Note on the Cochran Q test. J Am Statistical Assoc 329:155–160
Trotti LM, Staab BA, Rye DB (2013) Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia. J Clin Sleep Med 9:789–795
Acknowledgements
This work was supported by the project Ministry of Health, Czech Republic (00023736, IHBT).
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Vrana, M., Siffnerova, V., Pecherkova, P. et al. Distribution of HLA-DQB1 in Czech Patients with Central Hypersomnias. Arch. Immunol. Ther. Exp. 64 (Suppl 1), 89–98 (2016). https://doi.org/10.1007/s00005-016-0435-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00005-016-0435-5